Monday, 03 August 2020

Abcam, BrickBio to include conjugation-ready sites into recombinant antibodies

08 November 2019 | News

Together, the organizations will industrialize the technology to serve both the research and diagnostic markets

Abcam plc, a global innovator in life science reagents and tools, is pleased to announce a strategic partnership with BrickBio, experts in site-specific protein modification and a Tiger Gene portfolio company, covering the use of BrickBio's proprietary platform for introducing conjugation-ready sites into antibodies and other proteins in both mammalian and bacterial expression systems.

Under the partnership, Abcam will have exclusive rights to the platform for the creation of novel conjugation-ready recombinant products for the research tools market, as well as rights to commercialize the platform across its recombinant antibody and protein portfolio for diagnostic use.  In addition, Abcam will make a financial investment in BrickBio and work together with the BrickBio team to further industrialize the platform. 

BrickBio's platform provides an unparalleled ability to site-selectively modify proteins in a broad range of eukaryotic and bacterial cell lines. Using a proprietary engineered tRNA synthetase/tRNA pair, the platform can readily incorporate unnatural amino acids that can then be coupled to a second molecule for labeling or other research applications, or to create protein-conjugate therapeutics including Antibody-Drug-Conjugates (ADCs).   


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account